NDC product
FILSPARI
NDC 68974-200 · Travere Therapeutics, Inc.
Key facts
| Product NDC | 68974-200 |
|---|---|
| Proprietary name | FILSPARI |
| Nonproprietary name | sparsentan |
| Substances | SPARSENTAN |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Travere Therapeutics, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA216403 |
| Pharmacologic classes | Angiotensin 2 Receptor Blocker [EPC], Angiotensin 2 Type 1 Receptor Antagonists [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA] and 3 more |
| Marketing start | Feb 17, 2023 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: